A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis

Ruxolitinib, a potent Janus kinase 1/2 inhibitor, resulted in rapid and durable improvements in splenomegaly and disease-related symptoms in the 2 phase III COMFORT studies. In addition, ruxolitinib was associated with prolonged survival compared with placebo (COMFORT-I) and best available therapy (...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Haematologica
Autors principals: Vannucchi, Alessandro M., Kantarjian, Hagop M., Kiladjian, Jean-Jacques, Gotlib, Jason, Cervantes, Francisco, Mesa, Ruben A., Sarlis, Nicholas J., Peng, Wei, Sandor, Victor, Gopalakrishna, Prashanth, Hmissi, Abdel, Stalbovskaya, Viktoriya, Gupta, Vikas, Harrison, Claire, Verstovsek, Srdan
Format: Artigo
Idioma:Inglês
Publicat: Ferrata Storti Foundation 2015
Matèries:
Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4800694/
https://ncbi.nlm.nih.gov/pubmed/26069290
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2014.119545
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars